Research deep dive · Updated June 2026
The mitochondrial peptides: MOTS-c, SS-31 & cellular energy
Inside nearly every cell are tiny power plants — mitochondria — that turn food and oxygen into usable energy. As we age, they get less efficient: they leak more, produce more cellular "rust," and make less power. Researchers now consider mitochondrial decline one of the core engines of aging itself, underlying everything from the afternoon slump to muscle loss to a stiffening heart. Two peptides sit at the center of the research: MOTS-c and SS-31.
MOTS-c
A peptide written into mitochondrial DNA — the "exercise mimic."
Why researchers find it exciting
This is one of the field's most remarkable discoveries: MOTS-c is a 16-amino-acid peptide encoded inside your mitochondria's own DNA, found only in 2015.7 It flips on AMPK, the cell's master energy switch, and travels to the nucleus under stress to turn on protective antioxidant genes. It's also exercise-induced: one bout of hard exercise raised MOTS-c in human muscle roughly twelve-fold.8 Given to old mice, it nearly doubled running endurance and improved insulin sensitivity and muscle function — and, fittingly, its levels fall about 21% by our 70s–80s.9
The state of the evidence
The dramatic performance results are in mice and cells; human data are observational, and researchers are still hunting for its cellular receptor. No clinical trials, no approved use. The most reliable way to raise your MOTS-c today is the very thing it imitates — exercise.
SS-31 (Elamipretide)
A tiny peptide that homes in on the mitochondria's inner membrane.
Why researchers find it exciting
SS-31 is a 4-amino-acid peptide engineered to bind cardiolipin, a fat found almost only in the inner mitochondrial membrane, where it helps keep the energy machinery's structure intact and curbs oxidative damage.13 The animal data are striking: in 24-month-old mice, eight weeks of SS-31 reversed age-related heart stiffness and restored muscle mitochondrial function and exercise tolerance — late-life "rejuvenation."14
The state of the evidence
This is the most clinically advanced peptide of the whole group — and in September 2025 it earned its first FDA approval (as elamipretide, for the rare Barth syndrome), a real milestone for the field.15 Its broader anti-aging uses (heart, muscle, eye) are still being worked out in the clinic and not yet confirmed. Note: the "SS-31" sold as a research chemical isn't the approved drug.
Why this matters after 50
If joint peptides are about repair, the mitochondrial peptides are about energy — the fuel behind stamina, strength and metabolic flexibility, all of which lean on healthy mitochondria. That's why this corner of research speaks to the fatigue, the harder time staying lean, and the slow muscle drift that so many people notice after 50. The honest read: the mechanisms are elegant, the animal data are genuinely exciting, and the human story is still being written — with SS-31 the furthest along. Worth following closely, exploring carefully, and pairing with the things already proven to keep mitochondria healthy: exercise, sleep and good nutrition.
Explore it the careful way
Local, and handled for you
We deliver same-day in Central Florida on orders of $500 or more, and our managed service handles the prep. Free consultations, real people.
For research use only. Not for human consumption. Nothing here is medical advice.
Selected sources:
7. Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metab, 2015.
8. Reynolds JC et al. MOTS-c is an exercise-induced regulator of age-dependent physical decline. Nat Commun, 2021.
9. MOTS-c in Human Aging and Age-Related Diseases. Int J Mol Sci, 2022.
13. Mitchell W et al. SS-31 binds lipid bilayers and modulates surface electrostatics. J Biol Chem, 2020.
14. Chiao YA et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife, 2020.
15. Karaa A et al. Elamipretide in Primary Mitochondrial Myopathy (MMPOWER-3). Neurology, 2023; FDA accelerated approval of elamipretide (Barth syndrome), Sept 2025.
For research use only. Not for human consumption. Statements describe published research and are not claims of efficacy or safety in humans. Consult a licensed physician.